Shots:
THX has granted Biocodex an exclusive global license to develop & commercialize Batten-1 for juvenile Batten disease (CLN3), along with exclusive US & Canada rights to develop & commercialize TX01 for Gaucher & Niemann-Pick type CÂ disease
As per the deal, THX will lead clinical development with financial & scientific support from Biocodex, which will…
